prostate cancer (nmHSPC)
Oncology · 2024–2026
2decisions
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enzalutamide Treatment of non-metastatic hormone sensitive prostate cancer (m0HSPC) with high-risk biochemical recurrence (PSA doubling time ≤9 months) in combination with… | Mar 2026 | Recommended with restriction | no section in document |
| enzalutamide Treatment of patients with non-metastatic hormone-sensitive prostate cancer (m0HSPC) with high-risk biochemical recurrence (BCR), defined by prostate-specific… | Nov 2024 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group Australia |
Who spoke
Rare Cancers Australia · Medical Oncology Group Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.